MGLL and Alzheimer disease: Moreover, since 2‐AG displays anti‐inflammatory and neuroprotective properties, its degradative enzyme MAGL has been proposed as a therapeutic target in AD to enhance 2‐AG tone, and hence neuroprotection, with promising results in preclinical models (Chen et al., 2012; Hashem et al., 2021).